What's Going On With Windtree Therapeutics (WINT) Stock?

Windtree Therapeutics Inc WINT shares are trading higher by 36.5% to $2.03 during Monday’s session after the company regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing.

What To Know: The biotechnology company, which focuses on innovative therapies for critical conditions, received official notice from Nasdaq confirming that it met the necessary criteria.

Windtree had initially fallen out of compliance on December 4, 2024, after its stock traded below the required $1.00 minimum closing bid price for 30 consecutive days.

What Else: To restore compliance, the company needed to maintain a minimum bid price of $1.00 for at least 10 consecutive trading days. Windtree successfully met this benchmark as of February 21.

While the company is now in good standing, Nasdaq will continue monitoring it until March 20, 2026.

Read Also: US Stocks Likely To Open Higher As Trump May Soften Tariff Plans: Analysts Brush Off Bear Hug Fears

How To Buy WINT Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Windtree Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, WINT has a 52-week high of $737.44 and a 52-week low of $1.45.